文献速递心脑血管急症重症综合管理与镇静镇痛

复温速率对接受33°C目标温度管理的心电可除颤性心脏骤停患者白细胞介素-6水平的影响:ISOCRATE先导性随机对照试验

Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial.
PubMed 文献 · Crit Care · 2021-12-17
一句话结论心电可除颤性院外心脏骤停复苏后昏迷患者,33°C低温后以0.25°C/h复温较0.50°C/h未降低血清IL-6水平,90天神经功能结局无显著差异。

ISOCRATE为单中心随机对照试验,2016-2020年纳入50例心电可除颤性院外心脏骤停复苏后昏迷患者,比较33°C目标温度管理后以0.50°C/h与0.25°C/h复温对全身炎症的影响。主要终点为达到33°C后24-48小时血清IL-6曲线下面积,两组相似(12,389 [7256-37,200] vs. 8859 [6825-18,088] pg/mL·h,P=0.55)。90天良好脑功能(CPC)比例两组均为52.0%(13/25,95%CI 31.3-72.2%,P=0.99),48小时血清神经丝轻链水平亦无显著差异(76.0 [25.5-3074.0] vs. 192 [33.6-4199.0] pg/mL,P=0.43)。作者认为更慢复温未降低心电可除颤性心脏骤停后血清IL-6水平,尚需进一步RCT明确最佳TTM策略。

要点

  • 心电可除颤性院外心脏骤停复苏后昏迷患者,33°C低温后0.25°C/h复温较0.50°C/h未降低血清IL-6曲线下面积(12,389 [7256-37,200] vs. 8859 [6825-18,088] pg/mL·h,P=0.55)。
  • 90天良好脑功能(CPC)比例0.25°C/h组与0.50°C/h组均为52.0%(13/25,95%CI 31.3-72.2%),P=0.99,无显著差异。
  • 48小时血清神经丝轻链水平两组无显著差异(0.25°C/h组76.0 pg/mL [25.5-3074.0] vs. 0.50°C/h组192 pg/mL [33.6-4199.0],P=0.43)。
  • 作者结论:更慢复温未降低心电可除颤性心脏骤停后血清IL-6水平,尚需进一步RCT明确最佳TTM策略。

适用人群与场景

  • 心电可除颤性院外心脏骤停复苏后仍昏迷的患者,2016-2020年纳入单中心RCT。

处置流程与药物剂量

  • 目标温度管理33°C后,0.25°C/h组以0.25°C/h复温,0.50°C/h组以0.50°C/h复温。

研究设计与关键结果

  • ISOCRATE为单中心随机对照试验,随机50例心电可除颤性院外心脏骤停复苏后昏迷患者,比较33°C后0.50°C/h与0.25°C/h复温。
  • 主要终点血清IL-6曲线下面积(达到33°C后24-48小时)两组相似:12,389(7256-37,200)vs. 8859(6825-18,088)pg/mL·h,P=0.55。
  • 90天良好CPC比例:0.25°C/h组13/25(52.0%,95%CI 31.3-72.2%)vs. 0.50°C/h组13/25(52.0%,95%CI 31.3-72.2%),P=0.99。
  • 48小时血清神经丝轻链水平:0.25°C/h组76.0 pg/mL(25.5-3074.0)vs. 0.50°C/h组192 pg/mL(33.6-4199.0),P=0.43。

证据类型、等级与局限

  • 证据类型:先导性随机对照试验(单中心)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,心电可除颤性心脏骤停后33°C低温患者以0.25°C/h复温较0.50°C/h未降低血清IL-6水平,90天功能结局或死亡率与更慢复温无关联;尚需进一步RCT明确最佳TTM策略。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: While targeted temperature management (TTM) has been recommended in patients with shockable cardiac arrest (CA) and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We compared serum levels of the proinflammatory cytokine interleukin-6 (IL6) measured with two rewarming rates after TTM at 33 °C in patients with shockable out-of-hospital cardiac arrest (OHCA).

METHODS: ISOCRATE was a single-center randomized controlled trial comparing rewarming at 0.50 °C/h versus 0.25 °C/h in patients coma after shockable OHCA in 2016-2020. The primary outcome was serum IL6 level 24-48 h after reaching 33 °C. Secondary outcomes included the day-90 Cerebral Performance Category (CPC) and the 48-h serum neurofilament light-chain (NF-L) level.

RESULTS: We randomized 50 patients. The median IL6 area-under-the-curve was similar between the two groups (12,389 [7256-37,200] vs. 8859 [6825-18,088] pg/mL h; P = 0.55). No significant difference was noted in proportions of patients with favorable day-90 CPC scores (13/25 patients at 0.25 °C/h (52.0%; 95% CI 31.3-72.2%) and 13/25 patients at 0.50 °C/h (52.0%; 95% CI 31.3-72.2%; P = 0.99)). Median NF-L levels were not significantly different between the 0.25 °C/h and 0.50 °C/h groups (76.0 pg mL, [25.5-3074.0] vs. 192 pg mL, [33.6-4199.0]; P = 0.43; respectively).

CONCLUSION: In our RCT, rewarming from 33 °C at 0.25 °C/h, compared to 0.50 °C/h, did not decrease the serum IL6 level after shockable CA. Further RCTs are needed to better define the optimal TTM strategy for patients with CA. Trial registration ClinicalTrials.gov, NCT02555254 . Registered September 14, 2015.

TAKE-HOME MESSAGE: Rewarming at a rate of 0.25 °C/h, compared to 0.50 °C, did not result in lower serum IL6 levels after achievement of hypothermia at 33 °C in patients who remained comatose after shockable cardiac arrest. No associations were found between the slower rewarming rate and day-90 functional outcomes or mortality. 140-character Tweet: Rewarming at 0.25 °C versus 0.50 °C did not decrease serum IL6 levels after hypothermia at 33 °C in patients comatose after shockable cardiac arrest.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Lascarrou JB, Guichard E, Reignier J, et al. Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 °C: the ISOCRATE pilot randomized controlled trial. Crit Care. 2021. PMID: 34920723. doi:10.1186/s13054-021-03842-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。